Eli Lilly (LLY) Cites MFN Policy Impact on European Weight-Loss Drug Launch

Eli Lilly (LLY) announced on June 23, 2026, that the Trump administration's "Most-Favored-Nation" (MFN) drug pricing policy will complicate its pricing and reimbursement negotiations for new drugs in Europe. Despite these challenges, the pharmaceutical giant plans to launch its oral weight-loss drug in Europe and the UK between H2 2026 and early 2027, pending regulatory approval, while continuing to pursue public healthcare coverage. Eli Lilly International EVP Patrik Jonsson stated the MFN policy, linking some U.S. drug prices to lower international rates, will affect all new drug launches. The company aims for public insurance coverage but will also utilize telehealth, e-commerce, and direct-to-consumer channels, acknowledging obesity treatment is often self-funded outside the U.S. Lilly previously agreed to MFN-compliant pricing, referencing U.S. net prices adjusted for local income. This strategy unfolds amid rising demand for weight-loss drugs and ongoing U.S.-Europe drug pricing disputes.